Identification of CD245 as myosin 18A, a receptor for surfactant A: A novel pathway for activating human NK lymphocytes.

Fiche publication

Date publication

mai 2016

Journal

Oncoimmunology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr GARBAR Christian , Pr MERROUCHE Yacine , Pr BENSUSSAN Armand

Tous les auteurs :
De Masson A, Giustiniani J, Marie-Cardine A, Bouaziz JD, Dulphy N, Gossot D, Validire P, Tazi A, Garbar C, Bagot M, Merrouche Y, Bensussan A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/27467939

Résumé

CD245 is a human surface antigen expressed on peripheral blood lymphocytes, initially delineated by two monoclonal antibodies DY12 and DY35. Until now, CD245 molecular and functional characteristics remained largely unknown. We combined immunological and proteomic approaches and identified CD245 as the unconventional myosin 18A, a highly conserved motor enzyme reported as a receptor for the surfactant protein A (SP-A), that plays a critical role in cytoskeleton organization and Golgi budding. We report that the recruitment of CD245 strongly enhanced NK cell cytotoxicity. Further, we show that the enhancement of the NK lymphocytes killing ability toward CD137-ligand expressing target cells could result from the induction of CD137 expression following CD245 engagement. The SP-A receptor could therefore represent a novel and promising target in cancer immunotherapy.